US5672659A
(en)
*
|
1993-01-06 |
1997-09-30 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US5863985A
(en)
*
|
1995-06-29 |
1999-01-26 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
IL110787A0
(en)
*
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
GB2281697A
(en)
*
|
1993-09-14 |
1995-03-15 |
Euro Celtique Sa |
Laxative compositions in capsules
|
WO1995021629A1
(en)
*
|
1994-02-08 |
1995-08-17 |
Amgen Inc. |
Oral delivery of chemically modified proteins
|
USRE38827E1
(en)
|
1994-07-27 |
2005-10-11 |
3M Innovative Properties Company |
Adhesive sealant composition
|
US5583114A
(en)
|
1994-07-27 |
1996-12-10 |
Minnesota Mining And Manufacturing Company |
Adhesive sealant composition
|
DE19514087A1
(de)
*
|
1995-04-13 |
1996-10-17 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
|
US5747639A
(en)
*
|
1996-03-06 |
1998-05-05 |
Amgen Boulder Inc. |
Use of hydrophobic interaction chromatography to purify polyethylene glycols
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
US6867181B1
(en)
|
1997-06-02 |
2005-03-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US20050158273A1
(en)
*
|
1997-09-25 |
2005-07-21 |
Harris J. M. |
Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
|
US6066673A
(en)
*
|
1998-03-12 |
2000-05-23 |
The Procter & Gamble Company |
Enzyme inhibitors
|
PL200586B1
(pl)
|
1998-10-16 |
2009-01-30 |
Biogen Idec Inc |
Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
|
AU762616B2
(en)
|
1998-10-16 |
2003-07-03 |
Biogen Ma Inc. |
Polymer conjugates of interferon beta-1a and uses
|
DE10082068C5
(de)
*
|
1999-07-01 |
2009-02-05 |
Asahi Kasei Kabushiki Kaisha |
Niedermolekulares Oxymethylen-Polymeres und Zusammensetzung mit einem Gehalt an diesem Polymeren und Verfahren zur Herstellung
|
DE19936715A1
(de)
*
|
1999-08-06 |
2001-02-15 |
Ticona Gmbh |
Emissionsarme eingefärbte Polyoxymethylen-Formmassen
|
US8614291B2
(en)
*
|
1999-08-10 |
2013-12-24 |
Poly-Med, Inc. |
Phosphorylated polymers and conjugates thereof
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6555660B2
(en)
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6646110B2
(en)
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
CN1188172C
(zh)
|
2000-01-10 |
2005-02-09 |
马克西根控股公司 |
G-csf偶联物
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
MXPA03007619A
(es)
|
2001-02-27 |
2003-12-04 |
Maxygen Aps |
Nuevas moleculas similares a interferon beta.
|
DK1421175T3
(da)
*
|
2001-06-28 |
2009-03-23 |
Mountain View Pharmaceuticals |
Polymerstabiliserede proteinaser
|
NZ530545A
(en)
|
2001-07-11 |
2006-10-27 |
Maxygen Holdings Ltd |
Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
|
WO2003033539A1
(fr)
*
|
2001-10-16 |
2003-04-24 |
Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Rossiiskoi Akademii Nauk |
Composition pour immobilisation par polymerisation de macromolecules biologiques et procede de fabrication correspondant
|
GEP20074024B
(en)
|
2002-01-18 |
2007-01-10 |
Biogen Idec Inc |
Polyalkylene glycol comprising a radical for conjugation of biologically active compound
|
EP1585817B1
(en)
*
|
2002-02-20 |
2009-09-02 |
The General Hospital Corporation |
Conjugates comprising a biodegradable polymer and uses therefor
|
AU2003240439B2
(en)
|
2002-06-21 |
2009-05-21 |
Novo Nordisk Health Care Ag |
Pegylated factor VII glycoforms
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
RS20050501A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
WO2004060299A2
(en)
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of interferon-beta with enhanced biological potency
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
SI1696947T1
(sl)
|
2003-12-19 |
2014-05-30 |
F. Hoffmann-La Roche Ag |
Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
|
AU2005211385B2
(en)
|
2004-02-02 |
2008-12-11 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
WO2006009901A2
(en)
|
2004-06-18 |
2006-01-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
US7638299B2
(en)
|
2004-07-21 |
2009-12-29 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
ATE542920T1
(de)
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Modifiziertes menschliches wachstumshormon
|
EP1836298B1
(en)
*
|
2004-12-22 |
2012-01-18 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
MX2007007591A
(es)
|
2004-12-22 |
2007-07-25 |
Ambrx Inc |
Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
|
EP1848461A2
(en)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
CA2604696C
(en)
|
2005-04-15 |
2015-03-24 |
Interface Biologics, Inc. |
Polymer-biologically active agent complexes for localized delivery of said biologically active agent
|
MX2007015156A
(es)
*
|
2005-06-01 |
2008-02-15 |
Maxygen Holdings Ltd |
Polipeptidos g-csf pegilados y metodos para la produccion de los mismos.
|
CN103030690A
(zh)
*
|
2005-06-03 |
2013-04-10 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
KR101285904B1
(ko)
*
|
2005-08-18 |
2013-07-15 |
암브룩스, 인코포레이티드 |
tRNA 조성물 및 이의 용도
|
CN101400646A
(zh)
*
|
2005-11-08 |
2009-04-01 |
Ambrx公司 |
用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
|
US20090018029A1
(en)
*
|
2005-11-16 |
2009-01-15 |
Ambrx, Inc. |
Methods and Compositions Comprising Non-Natural Amino Acids
|
CN105384807A
(zh)
*
|
2005-12-14 |
2016-03-09 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
AU2007216998B8
(en)
|
2006-02-21 |
2013-12-19 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
CN104593348A
(zh)
|
2006-05-24 |
2015-05-06 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内半寿期的因子ix类似物
|
AU2007292903B2
(en)
*
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
JP5451390B2
(ja)
*
|
2006-09-08 |
2014-03-26 |
アンブルックス,インコーポレイテッド |
脊椎動物細胞内におけるサプレッサーtrnaの転写
|
SG174781A1
(en)
*
|
2006-09-08 |
2011-10-28 |
Ambrx Inc |
Hybrid suppressor trna for vertebrate cells
|
KR101476472B1
(ko)
*
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
CA2685596A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
NZ584825A
(en)
|
2007-11-20 |
2013-03-28 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
JP5702150B2
(ja)
|
2008-02-08 |
2015-04-15 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾されているレプチンポリペプチドおよびそれらの使用
|
JP5680534B2
(ja)
|
2008-07-23 |
2015-03-04 |
イーライ リリー アンド カンパニー |
修飾されているウシg−csfポリペプチドおよびそれらの使用
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
AU2009296267B2
(en)
|
2008-09-26 |
2013-10-31 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
MX346786B
(es)
|
2010-08-17 |
2017-03-31 |
Ambrx Inc |
Polipeptidos de relaxina modificados y sus usos.
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
MX2014000031A
(es)
|
2011-07-01 |
2014-07-09 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos.
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
US8779070B2
(en)
|
2012-07-31 |
2014-07-15 |
Empire Technology Development Llc |
Alkyl ether compositions and methods of use
|
WO2014021844A1
(en)
*
|
2012-07-31 |
2014-02-06 |
Empire Technology Development Llc |
Alkyl ether compositions and methods of use
|
EP4074728A1
(en)
|
2012-08-31 |
2022-10-19 |
Sutro Biopharma, Inc. |
Modified peptides comprising an azido group
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
KR102637699B1
(ko)
|
2014-10-24 |
2024-02-19 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
SG11201907209QA
(en)
|
2017-02-08 |
2019-09-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
PL3849614T3
(pl)
|
2018-09-11 |
2024-04-22 |
Ambrx, Inc. |
Koniugaty polipeptydu interleukiny-2 i ich zastosowania
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
EP3923991A1
(en)
|
2019-02-12 |
2021-12-22 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|